mHSPC VL

Selection of Androgen Deprivation Therapy for Use in Advanced Prostate Cancer - Bertrand Tombal

Details
Joining Thomas Keane, MBBCh, FRCSI, FACS, diving into the data reported in the Phase III HERO trial is Bertrand Tombal, MD, PhD. In this conversation, Dr. Tombal drives awareness in the urology community on the use of oral relugolix and the benefits to patients. He discusses the clinical implications of the trial data, intermittent androgen deprivation therapy, the relevance of testosterone surge,...

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer - Matthew Deek & Phuoc Tran

Details
Matthew Deek and Phuoc Tran join Charles Ryan to discuss their recent paper "The Mutational Landscape of Metastatic Castration-Sensitive Prostate Cancer: The Spectrum Theory Revisited" published in European Urology. The aim of this study was to characterize the somatic mutational landscape across the disease spectrum of metastatic castration-sensitive prostate cancer (mCSPC) to elucidate a biologi...

Standard of Care in the Treatment of Metastatic Hormone-Sensitive Prostate Cancer - Michael Morris & Christopher Sweeney

Details
Michael Morris, MD, and Christopher Sweeney, MBBS join Alicia Morgans, MD, MPH in a discussion on the treatment of metastatic hormone-sensitive prostate cancer. Dr. Sweeney shares his perspective on the use of combination therapy, in addition to traditional ADT, and how he approaches treatment decisions Dr. Morris discusses the latest data in this space coming from the CHAARTED and STAMPEDE studie...

Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer - Evan Yu

Details
Tom Keane welcomes Evan Yu to discuss the newest therapeutic options for patients with metastatic hormone-sensitive prostate cancer. Dr. Yu details the most crucial studies to date demonstrating improved OS in mHSPC patients, including the ARCHES , ENZAMET , STAMPEDE , and TITAN clinical trials. Additionally, he touches on the survival benefit shown in the CHAARTED trial. Dr. Yu provides a compreh...

Categorizing Patients with Hormone-Sensitive Prostate Cancer - Christopher Sweeney

Details
Christopher Sweeney joins Charles Ryan to discuss the topic of hormone-sensitive prostate cancer, specifically concentrating on how clinicians can confront and categorize their patients with the disease. In continuing the ongoing conversation of the optimal approach for a high-volume patient, Dr. Sweeney uses evidence from current clinical trials to outline optional alternatives to abiraterone tre...

Patient-reported Outcomes from TITAN: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer - Neeraj Agarwal

Details
In this conversation, Neeraj Agarwal joins Petros Grivas to discuss the Patient-Reported Outcomes (PRO) data from the TITAN study, Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. This data was presented at ESMO 2019. The Food and Drug Administration approved apalutamide (ERLEADA, Janssen Biotech, Inc) for patients with metastatic hormone-sensitive prostate cancer. (mHSPC) in Sept...

The Upheaval in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Chris Sweeney & Mary-Ellen Taplin

Details
Chris Sweeney, MD and Mary-Ellen Taplin, MD discuss their current approach to treating patients with metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Sweeney first evaluates whether or not the patient is fit for chemotherapy and what their access is to abiraterone which both have a clear benefit in high volume disease. Based on the CHAARTED data, Dr. Taplin does not offer chemotherapy in...

TITAN, TALAPRO-2 And Ongoing Clinical Trials for Prostate Cancer - Neeraj Agarwal

Details
Petros Grivas invites Neeraj Agarwal to discuss the TITAN trial which reported the first interim analysis at ASCO 2019. The TITAN trial is a "Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With metastatic hormone-sensitive prostate cancer (mHSPC). A total of 525 patients were assigned to receive apalutamide plus ADT and 527 to receive placebo plus ADT. The...

Clinical Implications of TITAN in mHSPC - Kim Chi and Michael Morris

Details
Kim Chi, MD discusses the first results from TITAN, A phase 3 randomized, placebo-controlled, double-blind study of apalutamide (APA) versus placebo (PBO) in men with metastatic hormone-sensitive prostate cancer (mHSPC), with Michael Morris, MD, and Alicia Morgans, MD. TITAN was designed to accrue patients with prior treatment for localized prostate cancer or prior docetaxel for mHSPC were allowed...

Combinatorial Treatment Strategies in mHSPC - Mary-Ellen Taplin

Details
Mary-Ellen Taplin and Alicia Morgans discuss treatment strategies in newly diagnosed metastatic prostate cancer patients. They review trial results and upcoming data that is expected to be reported out in the near future. Monotherapy with ADT is no longer the standard of care. They also discuss sequencing strategies in men who have progressed on therapy. Biographies: Mary-Ellen Taplin, MD, Chair,...